Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2010
Business Overview: Alphatec is a medical device company focused on surgical treatment of spine disorders, particularly those affecting the aging spine. The reporting period is significantly impacted by the acquisition of Scient'x S.A., a global medical device company based in France, which closed on March 26, 2010. This acquisition expanded Alphatec's product portfolio, international distribution network, and patent portfolio.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 |
|---|---|---|
| Revenues | $45.4 million | $80.7 million |
| Gross Profit | $28.8 million (63.5% margin) | $52.4 million (64.9% margin) |
| Operating Loss | $(3.1) million | $(6.6) million |
| Net Loss | $(3.0) million | $(7.7) million |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.11) |
| Cash and Cash Equivalents | $38.4 million (as of June 30, 2010) | N/A |
| Total Debt (Current + Long-term) | $34.2 million (net of discounts) | N/A |
| Working Capital | $77.4 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 54.5% year-over-year for the quarter and 41.0% for the six-month period. This growth is primarily driven by the inclusion of Scient'x sales ($9.7 million for the quarter) and expanded sales in Europe and Asia.
- Acquisition Impact: The acquisition of Scient'x resulted in significant increases in Goodwill (from $60.1M to $162.1M) and Intangible Assets (from $2.3M to $37.0M). The purchase price was approximately $154.3 million, paid primarily in stock.
- Expense Increases: Operating expenses rose due to the integration of Scient'x, including transaction-related expenses ($0.5M for the quarter, $3.6M for six months) and restructuring expenses ($0.8M for the quarter, $1.7M for six months) related to consolidating U.S. operations and exiting European distributor agreements.
- Foreign Currency: A significant foreign currency translation adjustment of $(13.6) million impacted comprehensive loss for the six months ended June 30, 2010, due to the Euro's decline against the U.S. dollar.
- Discontinued Operations: The company sold its subsidiary IMC Co. in April 2010, recording a gain of $0.2 million. Results for IMC Co. are now presented as discontinued operations.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: Management believes existing cash ($38.4 million) and available credit ($2.4 million) are sufficient to fund operations through at least June 30, 2011. In April 2010, the company completed a public offering raising approximately $43.1 million in net proceeds.
- Debt Covenants: The company amended its Credit Facility in March 2010. It must maintain a minimum fixed charge coverage ratio and a cash balance of at least $10 million with Silicon Valley Bank. The company was in compliance as of June 30, 2010.
- Integration Synergies: The company expects to realize cost reduction synergies from the integration of Scient'x, though future integration costs may be incurred.
- Legal Proceedings:
- Cross Medical Products: Alleged breach of patent license agreement regarding royalty payments.
- Orthotec: Ongoing litigation regarding successor liability for a prior judgment against Eurosurgical (a former Scient'x subsidiary).
- DAK Surgical: Lawsuit alleging entitlement to a change of control payment.
- False Claims Act: A qui tam complaint was dismissed without prejudice, but the DOJ continues its review of Scient'x USA's business practices.
- Market Risks: Exposure to foreign currency fluctuations (Euro, Yen) and commodity price volatility (titanium, stainless steel), though the latter is considered immaterial.
Key Facts for Investor Verification
- Acquisition Accounting: Verify the final allocation of the $154.3 million purchase price for Scient'x, as preliminary estimates for goodwill and intangibles are subject to revision.
- Debt Covenant Compliance: Monitor the company's ability to maintain the minimum fixed charge coverage ratio and the $10 million cash balance covenant under the amended Credit Facility.
- Integration Costs: Track actual restructuring and transaction costs against the $1.7 million and $3.6 million incurred in the first half of 2010 to assess the timeline for realizing synergies.
- Legal Exposure: Assess the potential financial impact of the ongoing litigation with Cross Medical Products, Orthotec, and DAK Surgical, as well as the outcome of the DOJ's review under the False Claims Act.
- Revenue Recognition in Europe: Note that revenues from European distributors are deferred until payment is received or due, which may impact the timing of revenue recognition compared to U.S. operations.